Abstract: Provided are methods of treating Fabry disease in a patient having severe renal impairment. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 200 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of less than once every week. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 100 mg free base equivalent of migalastat or salt thereof at a frequency of between about once every three days and about once every two weeks.

Abstract: Provided are methods for the treatment of Fabry disease in adolescent patient.

Abstract: Provided are methods of improving the pharmacokinetics of migalastat by limiting caffeine intake during migalastat therapy.

Abstract: Provided are methods for treatment of Fabry disease in a patient having renal impairment. Certain methods comprise administering to the patient about 100 mg to about 300 mg free base equivalent of migalastat or salt thereof at a frequency of greater than once every other day, such as once every four or seven days. Certain methods comprise measuring lyso-Gb3 and/or migalastat in one or more plasma samples from the patient.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: This invention presents a sulphurous acid generator which employs a concentric hopper and burn chamber in which the burn chamber is surrounded or substantially surrounded by the hopper. The present invention also employs means for substantially eliminating any discharge plume.

Abstract: A portable, foldable bath device for use on a bed or other support surface, includes: (a) a generally planar, flexible, water impervious bottom wall; (b) at least one flexible, water impervious side wall attached along one of its side edges to the periphery of the bottom wall; and (c) an aperture in one of the walls of the bath device, the aperture being occludable by a closure mechanism; wherein the side wall is convertible from a generally horizontal, planar, folded position adjacent the bottom wall to a generally vertical, erect, open position extending in an upward direction from the generally horizontal bottom wall.